{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:11:10Z","timestamp":1775236270406,"version":"3.50.1"},"reference-count":65,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2021,3,21]]},"DOI":"10.1080\/10428194.2020.1849682","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T05:56:00Z","timestamp":1606110960000},"page":"771-778","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond"],"prefix":"10.1080","volume":"62","author":[{"given":"Sean","family":"Harrop","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"Epworth Healthcare, Melbourne, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Polliack","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia;"},{"name":"University of Melbourne, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29334"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1979"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk030"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0237-1"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2900.2900"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.08.055"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.013"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.7.524"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.128"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt015"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373514"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5398"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4772.4772"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.004721"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"issue":"21","key":"e_1_3_2_23_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V120.21.435.435","article-title":"Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL study group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen","volume":"120","author":"Fischer K","year":"2012","unstructured":"Fischer K, Bahlo J, Fink A-M, et\u00a0al. Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL study group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Blood. 2012;120(21):435\u2013435.","journal-title":"Blood"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304683"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.218"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29605"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341032"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000336"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7511"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3761"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123930"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193615"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000360"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.304"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13264"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24052"},{"issue":"1","key":"e_1_3_2_43_1","first-page":"2767","article-title":"Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia","volume":"130","author":"Treon SP","year":"2017","unstructured":"Treon SP, Gustine J, Meid K, et\u00a0al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia. Blood. 2017;130(Supplement 1):2767.","journal-title":"Blood"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1530"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7920"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24405"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3795.bloodjournal8793795"},{"issue":"8","key":"e_1_3_2_49_1","first-page":"340","article-title":"Defective interferon-gamma production in patients with hairy cell leukaemia","volume":"66","author":"Netea MG","year":"2008","unstructured":"Netea MG, Hoitink O, Kullberg BJ, et\u00a0al. Defective interferon-gamma production in patients with hairy cell leukaemia. Neth J Med. 2008;66(8):340\u2013334.","journal-title":"Neth J Med"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21447"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.003"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0328-z"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-508754"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14207"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1803"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12908"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113135"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491"},{"issue":"3","key":"e_1_3_2_59_1","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma","volume":"35","author":"Dotan E","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T. 2010;35(3):148\u2013157.","journal-title":"P T"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00262"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16090"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.381"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.543717"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20483"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00092-8"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12120"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1849682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:23:18Z","timestamp":1732296198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1849682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3,21]]}},"alternative-id":["10.1080\/10428194.2020.1849682"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1849682","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}